Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
orlistat · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | ACTIVE_COMPARATOR | 60 mg orlistat |
| Arm 2 | ACTIVE_COMPARATOR | 120 mg orlistat (2 X 60 mg capsules) |
| Arm 3 | EXPERIMENTAL | orlistat experimental formulation |
| Name | Type | Description |
|---|---|---|
| 120 mg orlistat | DRUG | 2 X60 mg capsule |
| 60 mg orlistat | DRUG | 60 mg orlistat |
| orlistat experimental dose | DRUG | experimental |
Inclusion Criteria: * age: 18-60 years * Body Mass Index: 25-33 Exclusion Criteria: * gastrointestinal disease * organ transplant * HIV, hepatitis B or C * food allergies * alcohol or other substance abuse * smoking
Orlistat is a small molecule drug being studied for use in overweight individuals. It is in Phase 1 clinical development and is being developed by GSK plc. The drug is intended to address conditions related to being overweight, though it remains investigational and has not been approved for this use.
Orlistat is being developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker GSK. The company is conducting clinical trials to evaluate the drug's pharmacological equivalence in overweight individuals, with the drug currently in Phase 1 development.
Orlistat is in Phase 1 clinical development. It is an investigational drug being studied for overweight individuals, and it has not yet been approved by regulatory authorities. The Phase 1 trial has been completed, with 48 participants enrolled in the study.
Orlistat has one completed clinical trial, identified as NCT01550926, which assessed the pharmacologic equivalence of two orlistat dosage forms. The trial was a Phase 1, randomized, active-controlled study conducted in the United Kingdom with 48 participants who were overweight. The study has been completed.
Orlistat is the drug name used in clinical development by GSK plc. No alternative names have been reported for this drug in the context of its current Phase 1 trial. The drug is being studied specifically for its effects in overweight individuals.